Illustrative image.
Truvada
Emtricitabine / Tenofovir
$1893.00
200mg / 245mg · 3 × 30 tablets · 3 months supply
BrandBranded medicine· By Gilead SI
$631.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$7572a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningPosttreatment acute exacerbation of hepatitis b and risk of drug resistance with use of truvada for hiv-1 pre-exposure prophylaxis (prep) in undiagnosed early hiv-1 infection
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted.
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely in these individuals who discontinue TRUVADA. If appropriate anti-hepatitis B therapy may be warranted.
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with the use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed.
About Truvada
Overview
Truvada tablets contain two antiviral medicines, emtricitabine and tenofovir disoproxil fumarate. It is used with other antiretroviral medicines to treat HIV-1 infection in adults and children weighing at least 17 kg. It is also used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg, with a negative HIV-1 test required immediately before starting PrEP. The two ingredients block reverse transcriptase, an enzyme HIV-1 uses to make copies of itself.
What it treats
- HIV-1 infection, in combination with other antiretroviral medicines, in adults and children weighing at least 17 kg. - Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. A negative HIV-1 test is required immediately before starting PrEP.
Safety information
Side effects
Common side effects reported in people with HIV-1 include diarrhoea, nausea, tiredness, headache, dizziness, depression, difficulty sleeping, abnormal dreams and rash. In adults without HIV-1 taking Truvada for pre-exposure prevention (PrEP), headache, abdominal pain and weight loss were reported more often than with placebo. Serious side effects that warrant contacting a doctor include new or worsening kidney problems, including acute kidney failure and Fanconi syndrome; severe flare-ups of hepatitis B in people with that infection; bone loss and problems with bone mineralisation; and immune reconstitution syndrome, an immune-system reaction during HIV treatment that may need further assessment and treatment. Other serious risks include lactic acidosis (a build-up of lactic acid in the blood) and severe liver enlargement with fat accumulation.
FDA boxed warning
Posttreatment acute exacerbation of hepatitis b and risk of drug resistance with use of truvada for hiv-1 pre-exposure prophylaxis (prep) in undiagnosed early hiv-1 infection
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted.
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely in these individuals who discontinue TRUVADA. If appropriate anti-hepatitis B therapy may be warranted.
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with the use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
Before taking this medicine
Do not use Truvada for HIV-1 pre-exposure prophylaxis (PrEP) if your HIV-1 status is unknown or positive. This restriction applies to prevention use. Truvada can cause new or worsening kidney problems, including acute kidney failure and Fanconi syndrome. Avoid use with medicines that can harm the kidneys, including those used recently. Other conditions requiring caution include: - A history of fractures caused by weakened bones, osteoporosis risk or other risk factors for bone loss. Bone mineral density assessment may be needed. - Immune reconstitution syndrome during HIV-1 treatment, which may require further assessment and treatment. - Symptoms or test results suggesting lactic acidosis or serious liver toxicity, including severe liver enlargement with fat accumulation. Truvada must be discontinued if these occur. For PrEP, Truvada must be used as part of a comprehensive HIV prevention strategy, including other prevention measures and strict adherence to the prescribed regimen. There is also a risk of HIV-1 drug resistance. Mothers with HIV-1 infection, or suspected newly acquired HIV-1 infection, should not breastfeed because HIV may be transmitted to the baby.
Interactions
Tell your doctor if you take didanosine, atazanavir, other HIV medicines called protease inhibitors, or medicines for hepatitis C. Truvada can increase didanosine levels and the risk of toxicity. Your doctor may need to adjust didanosine treatment and monitor you closely. Truvada can lower atazanavir levels; the label specifies that atazanavir should be given with ritonavir when used with Truvada. Certain HIV protease inhibitors and hepatitis C medicines can increase tenofovir levels. Your doctor should monitor you for signs of toxicity if these medicines are used together.
Using Truvada
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ziagen
Abacavir
By GSK
Tablets · from 60 per pack
Also for antivirals
Brand $767.00
Baraclude
Enetecavir
By Bristol Myers
Tablets · from 30 per pack
Also for antivirals
Brand from $1,203.00
Isenrtess
Raltegravir
By MSD
Tablets · from 60 per pack
Also for antivirals
Brand $1,398.00
STRIBILD
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate
By Gilead Sciences
Tablets · from 30 per pack
Also for antivirals
Brand $1,405.00